ReviewNature reviews. Drug discovery2015
Advances in the development of influenza virus vaccines.
Review in Nature reviews. Drug discovery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07643688 (Expression of Inflammatory Markers in the Course of Acute Respiratory Viral Infections in Adults Aged 60 Years and Older), which is not on this map. Cited by 384 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Expression of Inflammatory Markers in the Course of Acute Respiratory Viral Infections in Adults Aged 60 Years and Older: a Prospective Observational Study in Primary Case
Who cites it
384 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Recent Advances in Nitrogen-Containing Heterocyclic Scaffolds as Antiviral Agents.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2024Pooled it
- Moving the Needle on Atherosclerotic Cardiovascular Disease and Heart Failure with Influenza Vaccination.Current atherosclerosis reports · 2021Pooled it
- Innate-like Gene Expression of Lung-Resident Memory CD8American journal of respiratory and critical care medicine · 2021Trial
- A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.Nature medicine · 2021Trial
- Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial.The Lancet. Infectious diseases · 2020Trial
- Harnessing conserved epitopes and multivalent antigen strategies for vaccine design: Lessons learned and opportunities.Human vaccines & immunotherapeutics · 2026Review
- Immunogenicity and efficacy of a rabies-based vaccine against highly pathogenic influenza H5N1 virus.Emerging microbes & infections · 2026Article
- Anti-idiotypic antibodies as molecular mimics of conserved influenza hemagglutinin epitopes.Protein science : a publication of the Protein Society · 2026Article
- Article
- Identification and computational analysis of B-cell epitopes on the hemagglutinin protein of the H3N2 influenza virus.Archives of microbiology · 2026Article
- Advancements in antiviral activity of aza-heterocyclic compounds: a review.Molecular diversity · 2026Review
- Clonal dynamics of germinal center refueling by secondary immunization.bioRxiv : the preprint server for biology · 2026Article
- Seasonal influenza mRNA vaccine induces stronger innate and comparable or better adaptive responses than licensed inactivated vaccines.NPJ vaccines · 2026Article
- Generation of an autophagy-targeting influenza A virus as live attenuated vaccine.Nature communications · 2026Article
- Multi-View Transformers for Structure-Aware HA-NA Drift Risk Scoring and Mutation Hotspot Mapping.Viruses · 2026Article
- Evaluation of Cross-Immunogenicity of Ferret Antisera Following Immunization with H5N1 Vaccine Strains.Vaccines · 2026Article
- Review
- DNA Nanostructure-Templated Multivalency Enables Broad-Spectrum Virus Inhibition.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- HIV Membrane-Proximal External Region Scaffolded Immunogen as Killed Whole-Cell Genome-Reduced Vaccines.Viruses · 2026Article
- Broad beta-CoV immunity and transmission blockade by a single-dose live-attenuated vaccine with atypical codon usage.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
324 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
Abstract
Influenza virus infections are a major public health concern and cause significant morbidity and mortality worldwide. Current influenza virus vaccines are an effective countermeasure against infection but need to be reformulated almost every year owing to antigenic drift. Furthermore, these vaccines do not protect against novel pandemic strains, and the timely production of pandemic vaccines remains problematic because of the limitations of current technology. Several improvements have been made recently to enhance immune protection induced by seasonal and pandemic vaccines, and to speed up production in case of a pandemic. Importantly, vaccine constructs that induce broad or even universal influenza virus protection are currently in preclinical and clinical development.
Indexed as
Identifiers
25722244What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.